web analytics
6.4 C
Munich
Wednesday, October 5, 2022

How Close is GeoVax Labs, Inc. (OTCMKTS:GOVX) to its Support Levels?

GeoVax Labs, Inc. (OTCMKTS:GOVX) made a big run back in October off its $0.20 base to highs over $0.50 per share. The Company entered the Ebola penny stock frenzy when they announced on October 2 that they had initiated a new program for the development of a safe and effective vaccine to prevent Ebola infection.

GOVX is once again trading just above established $0.20 support level on accelerating volume. The recent run to $0.50 and $0.20 support are welcome to shareholders who have endured years of downward drift since GOVX was $1.75 a share.

This one has been around for years. In 1996 they declared bankruptcy and lost their listing on a higher exchange. In the early 2000’s they traded as Dauphin Technology, Inc. focused on the design, manufacture and marketing of mobile hand-held and pen-based computers, components and accessories.

GeoVax Labs, Inc. (OTCMKTS:GOVX) is a clinical-stage biotechnology company developing innovative human vaccines using their novel DNA/MVA platform technology. GOVX primary focus is to develop vaccines that prevent and fight Human Immunodeficiency Virus (“HIV”) infections, and they have recently expanded their research and development efforts to include vaccines to prevent Ebola virus infection.

GeoVax’s unique, two component HIV vaccine, a recombinant DNA and a recombinant modified vaccinia Ankara (MVA), is designed to stimulate both anti-HIV antibody and anti-HIV T cell immune responses. GeoVax’s DNA and MVA vaccines are used in a prime/boost protocol in which priming is done with the DNA and boosting with the MVA. Priming and boosting can also be done with the MVA. Both the DNA and MVA express the three major proteins of the HIV virus: Gag, Pol, and Env, and produce non-infectious virus-like particles.

For more info on GOVX Please Subscribe below, also you should know we have Something Huge Coming!

GeoVax’s vaccines are unique in expressing virus-like particles that display the native form of the trimeric membrane-bound HIV-1 envelope glycoprotein. Clinical trials for GeoVax’s preventive HIV vaccines have been conducted by the US National Institutes of Health-supported HIV Vaccine Trials Network (HVTN) with funding from the National Institute of Allergy and Infectious Disease (NIAID). Overall, GeoVax’s vaccines, in various doses and combinations, have been tested in close to 500 humans.

GOVX most advanced vaccines under development address the clade B subtype of the HIV virus that is most prevalent in the United States and Western Europe. The vaccines are being evaluated to determine their potential to (a) prevent HIV infection and (b) to serve as an immunotherapy for individuals who are already infected with HIV.

On October 2 GOVX announced that is has initiated a new program for the development of a safe and effective vaccine to prevent Ebola infection. With a fast-moving epidemic threatening large populations in Africa, and no proven therapy available, an effective vaccine against Ebola is desperately needed.

GeoVax is developing two Ebola vaccines, GOVX-E301 and GOVX-E302. Both are recombinant MVA (modified vaccinia Ankara) vaccines designed to produce non-infectious virus-like particles (VLPs) displaying the Ebola virus glycoprotein. GOVX-E301 is being developed as a single-dose vaccine for epidemic response against the ZEBOV strain of Ebola, the virus responsible for the current outbreak. GOVX-E302 is being developed for routine immunization and is designed to protect against all three versions of Ebola known to be lethal in humans. GOVX-E302 is anticipated to be used in a two-dose regimen.

We have a Monster Pick Coming. Subscribe Right Now!

According to the 10Q filed in August it seems GOVX generates close to a million dollars annually from grant revenues. The Company continues to burn significantly more averaging close to a million dollars a quarter on r&d and administrative expenses. While the Company currently holds $1.3 million in the treasury serious dilution to fund future operations remains a threat.

Conclusion: GOVX is trading just over established $0.20 support levels; the stock exploded to over $0.50 back in October after the Company announced a new program for the development of a safe and effective vaccine to prevent Ebola infection.

Currently trading at a $5.6 million market valuation GOVX has seen almost a straight line drop from its highs near $2 a share in 2011 and might be ready for a significant move. It has already reversed once of $0.20 and investors are hoping it can do it again here. GOVX is a highly volatile stock with a history of explosive moves and deserves to be on investors closely watched.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in EKSO either long or short and we have not been compensated for this article.

geovax

More articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest article

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.